1. Adverse effects associated with lipid-lowering therapy: Evidence from a 6-year real world study. (August 2021) Authors: Barkas, F.; Anastasiou, G.; Koutsogianni, A.-D.; Liamis, G.; Elisaf, M.; Liberopoulos, E.N. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: An analysis from the hellas-fh. (August 2022) Authors: Anagnostis, P.G.; Rizos, C.; Skoumas, I.; Rallidis, L.; Tziomalos, K.; Skalidis, E.; Kotsis, V.; Doumas, M.; Kolovou, G.; Sfikas, G.; Garoufi, A.; Lambadiari, V.; Dima, I.; Kiouri, E.; Agapakis, D.; Zacharis, E.; Antza, C.; Kolovou, V.; Koumaras, C.; Bantouvakis, G. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Association of TG/HDL-C and TYG indices with the prevalence of atherosclerotic cardiovascular disease in adult patients with familial hypercholesterolemia. (August 2022) Authors: Rizos, C.; Liamis, G.; Skoumas, I.; Garoufi, A.; Rallidis, L.; Tziomalos, K.; Kolovou, G.; Skalidis, E.; Kotsis, V.; Doumas, M.; Lambadiari, V.; Anagnostis, P.G.; Sfikas, G.; Dima, I.; Kiouri, E.; Polychronopoulos, G.; Kolovou, V.; Zacharis, E.; Antza, C.; Koumaras, C. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CHADS2 and CHA2DS2-Vasc scores predict cardiovascular disease in statin-treated individuals without atrial fibrillation. (September 2016) Authors: Barkas, F.; Klouras, E.; Liamis, G.; Elisaf, M.; Liberopoulos, E. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Cholesterol levels of high-density lipoprotein (HDL-C), APOB/APOA1 ratio and cardiovascular risk in patients with familial hypercholesterolemia (FH): Data from the HELLAS-FH registry. (December 2020) Authors: Rizos, C.; Liamis, G.; Skoumas, I.; Rallidis, L.; Tziomalos, K.; Skalides, E.; Kotsis, V.; Garoufi, A.; Athyros, V.G.; Kolovou, G.; Sfikas, G.; Bilianou, E.; Koutagiar, I.; Kiouri, E.; Agapakis, D.; Zacharis, E.; Antza, C.; Attilakos, A.; Katsiki, N.; Koumaras, C. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Cholesterol target attainment according to the recent ESC/EAS guidelines: Evidence from clinical practice. (December 2020) Authors: Barkas, F.; Liamis, G.; Anastasiou, G.; Sakkas, N.; Liberopoulos, E. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical application of PCSK9 inhibitors in a specialized lipid clinic. (August 2018) Authors: Barkas, F.; Filippas-Ntekouan, S.; Liberopoulos, E.; Christopoulou, E.; Pantazi, A.; Tzavella, E.; Elisaf, M.; Liamis, G. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Clinical characteristics of patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. (December 2020) Authors: Rizos, C.; Liamis, G.; Skoumas, I.; Rallidis, L.; Tziomalos, K.; Skalides, E.; Kotsis, V.; Garoufi, A.; Athyros, V.G.; Kolovou, G.; Sfikas, G.; Bilianou, E.; Koutagiar, I.; Kiouri, E.; Agapakis, D.; Zacharis, E.; Antza, C.; Attilakos, A.; Katsiki, N.; Anagnostis, P. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients. (August 2022) Authors: Liontos, A.; Biros, D.; Papathanasiou, A.; Papagiannopoulos, C.; Klouras, E.; Athanasiou, L.; Tsourlos, S.; Filippas-Ntekouan, S.; Samanidou, V.; Kolios, N.-G.; Veliani, C.; Pappa, C.; Zarachi, A.; Christaki, E.; Liberopoulos, E.; Elisaf, M.; Milionis, H.; Liamis, G. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients. (August 2022) Authors: Liontos, A.; Filippas-Ntekouan, S.; Biros, D.; Kolios, N.-G.; Veliani, C.; Papagiannopoulos, C.; Samanidou, V.; Papathanasiou, A.; Tsourlos, S.; Athanasiou, L.; Pappa, C.; Pargana, E.; Nasiou, M.; Zarachi, A.; Tsiakas, I.; Christaki, E.; Elisaf, M.; Liberopoulos, E.; Milionis, H.; Liamis, G. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗